What is the recommended management for a patient with non‑obstructive coronary artery disease?

Management of Non-Obstructive Coronary Artery Disease

For patients with non-obstructive CAD found on angiography, long-term aspirin therapy and aggressive secondary prevention measures (statins targeting LDL-C <70 mg/dL, ACE inhibitors if indicated, lifestyle modifications) should be prescribed, with antiplatelet and anticoagulant therapy discontinued at physician discretion if no acute coronary syndrome is present.

Acute Management Context (UA/NSTEMI with Non-Obstructive CAD)

If the patient presented with unstable angina or NSTEMI and angiography reveals non-obstructive disease:

Antiplatelet Therapy

• Continue aspirin indefinitely 1
• Discontinue P2Y12 inhibitors (clopidogrel/ticagrelor) and IV GP IIb/IIIa inhibitors at physician discretion 1
• The guidelines explicitly state that for patients with evidence of coronary atherosclerosis (luminal irregularities, non-flow-limiting stenoses), long-term aspirin and secondary prevention measures should be prescribed 1

Anticoagulation

• Discontinue anticoagulant therapy (UFH, enoxaparin, fondaparinux, bivalirudin) at physician discretion 1

Long-Term Secondary Prevention (Critical Component)

Even without obstructive disease, the presence of atherosclerosis warrants aggressive risk modification:

Lipid Management

Target LDL-C <70 mg/dL as a reasonable option for very high-risk patients 2:

• Start high-intensity statin therapy
• If LDL-C goal not achieved on maximum tolerated statin dose, add ezetimibe 3, 4
• For patients at very high risk not at goal despite statin + ezetimibe, add PCSK9 inhibitor 3, 4
• Consider non-HDL-C target <100 mg/dL; if triglycerides 200-499 mg/dL, target non-HDL-C <130 mg/dL 2
• Add fibrate or niacin if high triglycerides (>200 mg/dL) or low HDL-C (<40 mg/dL) persist after LDL-lowering 2

ACE Inhibitors/ARBs

• Recommended in presence of hypertension, diabetes, or heart failure 3, 4
• Consider for all patients with documented atherosclerosis even if non-obstructive 5

Beta-Blockers

• Consider for symptomatic relief if angina persists 6, 5
• Particularly important if spontaneous coronary artery dissection (SCAD) is suspected as underlying mechanism 5

Lifestyle Modifications

• Restrict saturated fat to <7% of total calories
• Cholesterol intake <200 mg/day
• Increase soluble fiber (10-25 g/day)
• Add plant stanols/sterols (2 g/day) 2
• Trans fat <1% of caloric intake
• Weight management and increased physical activity 2

Special Consideration: ANOCA/INOCA Syndrome

If the patient has persistent anginal symptoms despite non-obstructive CAD and poor quality of life, the 2024 ESC guidelines provide a new paradigm:

Invasive Coronary Function Testing

Invasive CFT is recommended (Class I, Level B) to identify treatable endotypes 3, 7:

• Test for coronary microvascular dysfunction using adenosine (measure coronary flow reserve and microvascular resistance)
• Test for vasospasm using acetylcholine provocation 3, 7

Mechanism-Based Treatment

For Vasospastic Angina:

• Calcium channel blockers are first-line (Class I, Level A) 3
  • High-dose therapy: verapamil 240-480 mg/day, diltiazem 120-360 mg/day, or nifedipine 60-120 mg/day 8
  • Consider dual CCB therapy (non-dihydropyridine + dihydropyridine) if monotherapy insufficient 5
• Long-acting nitrates as adjunct 3
• Avoid beta-blockers in isolated vasospastic angina (may worsen spasm)

For Microvascular Dysfunction:

• Beta-blockers for symptom control 6, 5
• Calcium channel blockers 6
• ACE inhibitors 5
• Ranolazine for refractory symptoms 5
• Statins for plaque stabilization 5

For Syndrome X (Microvascular Angina):

• Nitrates, beta-blockers, and calcium channel blockers alone or in combination (Class I, Level B) 6
• Consider imipramine 50 mg at bedtime for refractory pain 6, 8
• Aminophylline may be considered 6

Common Pitfalls to Avoid

1. Do not dismiss non-obstructive CAD as benign - These patients have increased risk of MACE and require secondary prevention 9, 10, 11

2. Do not continue dual antiplatelet therapy long-term unless specific indication (e.g., recent SCAD with stenting) - Guidelines recommend aspirin alone for chronic management 1

3. Do not prescribe aspirin to truly low-risk patients - One study showed aspirin may be harmful in very low-risk non-obstructive CAD 11

4. Do not use beta-blockers as first-line for vasospastic angina - CCBs are superior and beta-blockers may worsen vasospasm 8, 5

5. Do not overlook the need for invasive functional testing in persistently symptomatic patients - This is now a Class I recommendation in 2024 ESC guidelines 3, 7

Risk Stratification Nuance

The evidence shows non-obstructive CAD exists on a risk continuum 9. Patients with extensive non-obstructive disease (multiple vessels with luminal irregularities) warrant more aggressive secondary prevention than those with minimal disease 11. The 2024 guidelines emphasize that 30% of patients with non-obstructive CAD and ≥20% 10-year ASCVD risk remain untreated with statins - a critical gap in care 12.

Cardiologist evaluation significantly increases appropriate statin prescription (OR 4.4) 12, suggesting these patients benefit from specialty referral for optimization of preventive therapy.